Sign inJoin waitlistJoin the waitlist

Daniel Benedetti

Director, Pediatric Ethics Initiative · Vanderbilt University Medical Center

Credentials: · · · · · ·

History

Center for Biomedical Ethics and Society · Vanderbilt University Medical Center
Present
Vanderbilt Univ Sch of Med
Present
Vanderbilt University Medical Center
Present

Pediatric Hematology Oncology
Boston Children's Hospital
2015–2018
Hematology/Oncology
Dana-Farber Cancer Institute
2017–2018
Seattle Children's Hospital
2014–2015
Seattle Children's Hospital
2011–2014
University of Washington
University of Washington School of Medicine
2007–2011
University of Pennsylvania
2003–2007

Research

An ERG (ets-related gene)-associated histone methyltransferase interacts with histone deacetylases 1/2 and transcription co-repressors mSin3A/B
Biochemical Journal · 2003 · 99 citations
Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2024 · 96 citations
Pediatric renal tumor epidemiology: Global perspectives, progress, and challenges
Review · Pediatric Blood & Cancer · 2023 · 23 citations

Elizabeth Mullen
12 papers
PE
Peter Erhlich
11 papers
James Geller
10 papers
Jeffrey Dome
10 papers
Harold Lovvorn
7 papers
Jennifer Aldrink
7 papers
Nicholas Cost
7 papers · 4 as a fellow
Lauren Parsons
6 papers
Arnold Paulino
5 papers
Ethan Smith
5 papers
John Kalapurakal
5 papers
KV
Kelly Vallance
5 papers

Clinical trials

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
Site PI · Recruiting · Phase 1, Phase 2
Milton S. Hershey Medical Center
2026–2035
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2029
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Site PI · Recruiting · Phase 2
Giselle Sholler
2024–2035